MILLBROOK, N.Y., Nov. 14, 2012 /PRNewswire/ -- Donald Fresne, President and CEO of Egenix, Inc., is pleased to announce the appointment of John Reid to its Board of Directors. John Reid retired from Colgate Palmolive as Chief Technological Officer, accountable for Global R&D, IT and the Supply Chain. Prior to that position he had developed Colgate's first corporate and divisional Strategic Plans before heading subsidiaries in Greece, the UK and the South Pacific, out of Australia. Earlier he helped write the first corporate and divisional Strategic Plans at Pfizer, before taking operational accountabilities in India and Bangladesh. Dr. Reid served on the Boards of Readers Digest and Minerals Technologies and taught "Practically Global" as an Adjunct Professor at NYU Stern. He has served on several not for profit Boards and is presently President of American Friends of Maungatautari. Reid was educated in New Zealand and took his D.Phil at Oxford, where he was a Rhodes Scholar and played rugby for the University against the New Zealand All Blacks. Dr. Reid will be a significant addition to the Egenix Board.
Egenix is a privately held, New York-based biotechnology company focused on the development of innovative cancer therapeutics. The company's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers. Our lead drug candidates inhibit the "translation initiation factor" eIF4E, specifically blocking production of multiple cancer promoting proteins and promoting apoptosis (programmed cell death) and upregulation of tumor suppressor genes. The company licensed this technology from Harvard Medical School in 2007. eIF4E is an attractive cancer therapeutic target because every function necessary for cancer growth and metastasis is influenced or mediated by a gene product that is regulated by this translation initiation factor. For more information please visit www.egenixinc.com.
SOURCE Egenix, Inc.